NESS ZIONA, Israel, September 8, 2015 /PRNewswire/ --
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Company’s CEO, Dr. Ron Babecoff, will participate in the Rodman & Renshaw 17th Annual Global Investment Conference, taking place at the St. Regis hotel in New York from September 8-10, 2015.
BiondVax CEO, Dr. Ron Babecoff, is scheduled to present on Thursday, September 10, 2015 at 10:25am Eastern Time. The corporate presentation which Dr. Babecoff will present at the conference is available for download from the investor relations section of BiondVax’s website.
At the conference there will be an opportunity for investors to meet one-on-one with Dr. Ron Babecoff. In addition, Dr. Babecoff will be meeting investors and analysts throughout the week on a non-deal roadshow in both Boston and New York. Investors interested in meeting with management should contact the Investor Relations team at BiondVax at biondvax@gkir.com.
About BiondVax Pharmaceuticals Ltd
BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
BiondVax’s technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
For further information, please contact:
Company Contact
Limor Chen, Director of BD
limor.c@biondvax.com
Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
kenny@biondvax.com
SOURCE Biondvax Pharmaceuticals Ltd
Help employers find you! Check out all the jobs and post your resume.
